Latest Breaking News On - Reduced ejection - Page 3 : comparemela.com

Empagliflozin (Jardiance®) receives MHRA approval for the treatment of heart failure with reduced ejection fraction

Cardiac Success Secures $5.2M for Transcatheter Ventricular Repair Device for Heart Failure Patients

Tailored, earlier heart failure rehab has physical, emotional benefits for patients

An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehab programs.

FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization

FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization Verquvo is the first soluble guanylate cyclase stimulator drug cleared by FDA to treat heart failure January 25, 2021 The U.S. Food and Drug Administration (FDA) approved Merck s Verquvo (vericiguat). It is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics.  The drug is supposed to reduce the risk of cardiovascular death and heart failure hospitalization in indicated patients  with symptomatic chronic heart failure and ejection fraction less than 45%. Vericiguat is a soluble guanylate cyclase (sGC) stimulator, and is the first drug in this class ro be cleared by the FDA for heart failure.